Generated Narrative

category: Laboratory

code: Therapeutic Implication

derivedFrom: Generated Summary: Laboratory; Genotype display name; effective: 2020-01-01; CYP2C19*2/*2

component

code: Medication assessed [ID]

value: clopidogrel

component

code: Genetic variation's effect on drug metabolism

value: Poor metabolizer

component

code: Conclusion text

value: For clopidogrel, individuals with this diplotype are expected to have significantly reduced platelet inhibition, increased residual platelet aggregation and increased risk for adverse cardiovascular events in response to clopidogrel. Alternative antiplatelet therapy (if no contraindication) is recommended. Refer to current guidelines for dosage and recommendations at https://cpicpgx.org/guidelines/guideline- for-clopidogrel-and-cyp2c19/